These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 34808345)

  • 1. Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
    Breder I; Wolf VLW; Soares AAS; de Carvalho LSF; Kimura-Medorima ST; Cintra RM; Barreto J; Munhoz DB; Cunha JS; Bonilha I; Coelho-Filho OR; Quinaglia T; Nadruz W; Guerra-Junior G; Muscelli E; Sposito AC;
    Diabetes Metab; 2022 Mar; 48(2):101304. PubMed ID: 34808345
    [No Abstract]   [Full Text] [Related]  

  • 2. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
    Neeland IJ; McGuire DK; Chilton R; Crowe S; Lund SS; Woerle HJ; Broedl UC; Johansen OE
    Diab Vasc Dis Res; 2016 Mar; 13(2):119-26. PubMed ID: 26873905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
    Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
    Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
    Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
    BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
    Shim CY; Seo J; Cho I; Lee CJ; Cho IJ; Lhagvasuren P; Kang SM; Ha JW; Han G; Jang Y; Hong GR
    Circulation; 2021 Feb; 143(5):510-512. PubMed ID: 33186508
    [No Abstract]   [Full Text] [Related]  

  • 10. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
    Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin Cut Risk of Worsening Heart Failure.
    Slomski A
    JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
    Fioretto P; Stefansson BV; Johnsson E; Cain VA; Sjöström CD
    Diabetologia; 2016 Sep; 59(9):2036-9. PubMed ID: 27306615
    [No Abstract]   [Full Text] [Related]  

  • 17. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
    O'Donoghue ML; Kato ET; Mosenzon O; Murphy SA; Cahn A; Herrera M; Tankova T; Šmahelová A; Merlini P; Gause-Nilsson I; Langkilde AM; McGuire DK; Wilding JPH; Leiter LA; Bhatt DL; Raz I; Sabatine MS; Wiviott SD
    Diabetologia; 2021 Jun; 64(6):1226-1234. PubMed ID: 33611623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
    N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
    Idzerda NMA; Stefansson BV; Pena MJ; Sjostrom DC; Wheeler DC; Heerspink HJL
    Nephrol Dial Transplant; 2020 Sep; 35(9):1570-1576. PubMed ID: 31005993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.